April Armstrong, MD, Professor and Chief of Dermatology at University of California-Los Angeles (UCLA), shares interim results from the TRACE study. Presented at the 2024 European Academy of Dermatology and Venereology (EADV) Congress in Amsterdam, the study found that the percentage of patients with baseline head and neck atopic dermatitis (AD) who had an Investigator’s Global Assessment score of 0 (clear) or 1 (almost clear) (IGA 0/1) increased from 1.4% at baseline to 33.6% at three months, 48.4% at six months, and 57.4% at nine months of treatment with tralokinumab (Adbry/Adtralza, Leo), regardless of previous biologic treatment.
